AU2009244091B2 - IGF-II/GF-IIE binding proteins - Google Patents

IGF-II/GF-IIE binding proteins Download PDF

Info

Publication number
AU2009244091B2
AU2009244091B2 AU2009244091A AU2009244091A AU2009244091B2 AU 2009244091 B2 AU2009244091 B2 AU 2009244091B2 AU 2009244091 A AU2009244091 A AU 2009244091A AU 2009244091 A AU2009244091 A AU 2009244091A AU 2009244091 B2 AU2009244091 B2 AU 2009244091B2
Authority
AU
Australia
Prior art keywords
igf
iie
protein
growth hormone
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009244091A
Other languages
English (en)
Other versions
AU2009244091A1 (en
Inventor
Timothy Adams
Edward Cohen
Leah Cosgrove
Daniel Dransfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Dyax Corp
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO, Dyax Corp filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of AU2009244091A1 publication Critical patent/AU2009244091A1/en
Application granted granted Critical
Publication of AU2009244091B2 publication Critical patent/AU2009244091B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2009244091A 2008-05-09 2009-05-08 IGF-II/GF-IIE binding proteins Ceased AU2009244091B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5195608P 2008-05-09 2008-05-09
US61/051,956 2008-05-09
US5342708P 2008-05-15 2008-05-15
US61/053,427 2008-05-15
US16318009P 2009-03-25 2009-03-25
US61/163,180 2009-03-25
PCT/US2009/043273 WO2009137758A2 (en) 2008-05-09 2009-05-08 Igf-ii/gf-iie binding proteins

Publications (2)

Publication Number Publication Date
AU2009244091A1 AU2009244091A1 (en) 2009-11-12
AU2009244091B2 true AU2009244091B2 (en) 2014-11-27

Family

ID=41265434

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009244091A Ceased AU2009244091B2 (en) 2008-05-09 2009-05-08 IGF-II/GF-IIE binding proteins

Country Status (6)

Country Link
US (1) US20110165145A1 (OSRAM)
EP (1) EP2296703A4 (OSRAM)
JP (2) JP5734180B2 (OSRAM)
AU (1) AU2009244091B2 (OSRAM)
CA (1) CA2723722A1 (OSRAM)
WO (1) WO2009137758A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2010045315A1 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
EP2376116B1 (en) 2008-12-12 2015-12-09 Boehringer Ingelheim International GmbH Anti-igf antibodies
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
KR101843248B1 (ko) * 2015-03-17 2018-03-29 고려대학교 세종산학협력단 흉선 기질 림프단백질 매개 신호전달을 제어하는 펩타이드 유도체 및 이를 포함하는 알러지 및 천식 질환 예방 및 치료용 약학 조성물
US10469309B1 (en) * 2016-04-28 2019-11-05 Servicenow, Inc. Management of computing system alerts

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492552A1 (en) * 1990-12-21 1992-07-01 Daiichi Pharmaceutical Co., Ltd. Anti-IGF-II monoclonal antibody

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3213359B2 (ja) * 1990-12-21 2001-10-02 第一製薬株式会社 抗ｉｇｆ−ｉｉモノクローナル抗体
US7438911B2 (en) * 2002-04-30 2008-10-21 Kyowa Hakko Kogyo Co., Ltd. Antibody against human insulin-like growth factor
WO2005018671A1 (ja) * 2003-08-21 2005-03-03 Kyowa Hakko Kogyo Co., Ltd. 癌転移阻害剤
WO2005028515A1 (ja) * 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
JPWO2005027970A1 (ja) * 2003-09-24 2007-11-15 協和醗酵工業株式会社 癌治療用医薬
US7612179B2 (en) * 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
AU2005215024B2 (en) * 2004-02-19 2011-07-21 Dyax Corp. Conformation specific antibodies
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
WO2007022172A1 (en) * 2005-08-17 2007-02-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that specifically bind igf-ii
ATE552853T1 (de) * 2005-12-13 2012-04-15 Medimmune Ltd Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
US8071323B2 (en) * 2006-04-07 2011-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that bind human insulin like growth factors and their use
US8178091B2 (en) * 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492552A1 (en) * 1990-12-21 1992-07-01 Daiichi Pharmaceutical Co., Ltd. Anti-IGF-II monoclonal antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUNDEEP KHOSLA ET AL: JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 87, no. 8, 1 August 2002 (2002-08-01 ), pages 3867-3870, *

Also Published As

Publication number Publication date
JP5734180B2 (ja) 2015-06-17
US20110165145A1 (en) 2011-07-07
CA2723722A1 (en) 2009-11-12
EP2296703A4 (en) 2012-09-05
WO2009137758A2 (en) 2009-11-12
WO2009137758A3 (en) 2010-03-18
AU2009244091A1 (en) 2009-11-12
JP2014077020A (ja) 2014-05-01
EP2296703A2 (en) 2011-03-23
JP2011523405A (ja) 2011-08-11

Similar Documents

Publication Publication Date Title
US8106168B2 (en) Metalloproteinase binding proteins
AU2009303453B2 (en) Use of IGF-II/IGF-IIE binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
JP6787795B2 (ja) 抗Ａｘｌ抗体
JP6787796B2 (ja) 抗Ａｘｌ抗体
KR20150036603A (ko) Rspo3 결합제 및 그의 용도
JP2011506614A (ja) Ｍｍｐ−１４結合タンパク質を含む、骨溶解性障害を処置するための組成物および方法
US20110165145A1 (en) Igf-ii/igf-iie binding proteins
CA2977621A1 (en) Antibody binding to tfpi and composition comprising the same
US10314909B2 (en) Combination therapy comprising an MMP-14 binding protein
US20220195037A1 (en) Compositions and methods for inhibiting cancer stem cells
JP2020508694A5 (OSRAM)
HK1123740B (en) Metalloproteinase binding proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired